mesalazine การใช้

• Standard treatment for active disease includes Mesalazine suppositories and cortisone foam ( Cortifoam ).
• Mesalazine is the active moiety of sulfasalazine, which is metabolized to sulfapyridine and mesalazine.
• Mesalazine is the active moiety of sulfasalazine, which is metabolized to sulfapyridine and mesalazine.
• Maintenance therapy is not recommended for those with a first episode that responded to the Mesalazine.
• If oral Mesalazine is still not working, prednisone is often given, starting at 40 60 mg / day.
• Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine.
• Mesalazine 1 g SUPP QHS or Cortifoam QHS / BID is continued until remission, with response seen usually within three weeks.
• Very rarely, use of mesalazine has been associated with an exacerbation of the symptoms of colitis, Stevens Johnson syndrome and erythema multiforme.
• Once the inflammation is successfully controlled, another drug to keep the disease in remission, such as mesalazine in UC, is the main treatment.
• Anti-inflammatory drugs, such as salicylates, Mesalazine, and systemic corticosteroids may be prescribed for people who do not respond to other drug treatment.
• Use of a transdermal nicotine patch without the addition of other standard treatments such as mesalazine has relapse occurrence rates similar to standard treatment without the use of nicotine.
• 5-ASA compounds, such as mesalazine and sulfasalazine, have shown to be of very little efficacy in the treatment of Crohn's disease, either for induction or for maintenance of remission.
• If further treatment is required, a combination of an immunosuppressive drug ( such as azathioprine ) with mesalazine ( which may also have an anti-inflammatory effect ) may be needed, depending on the patient.
• Therefore, 5-ASA and other derivatives of 5-ASA, are now usually preferred and given alone ( as mesalazine ), despite their increased cost, due to their more favourable side-effect profile.
• Because sulfasalazine and its metabolite mesalazine ( or 5-aminosalicylic acid ( 5-ASA ) ) are poorly absorbed into the bloodstream, it is surprising that the drug is effective against symptoms outside of the intestine.
• It has also been observed that mesalazine therapy helps to normalise the gut flora which is often abnormal in people who have IBS . The therapeutic benefits of mesalazine may be the result of improvements to the epithelial barrier function.
• It has also been observed that mesalazine therapy helps to normalise the gut flora which is often abnormal in people who have IBS . The therapeutic benefits of mesalazine may be the result of improvements to the epithelial barrier function.
• Like balsalazide, olsalazine is believed to deliver mesalazine, or 5-aminosalicylic acid ( 5-ASA ), past the small intestine, directly to the large intestine, which is the active site of disease in ulcerative colitis.
• Maintenance therapy is with Mesalazine 1g QHS or Q3HS . Those with anal irritation or discomfort from the suppositories may switch to oral medications, such as sulfasalazine, Mesalazine, or Colazol, although they are not as effective as suppositories for proctitis.
• Maintenance therapy is with Mesalazine 1g QHS or Q3HS . Those with anal irritation or discomfort from the suppositories may switch to oral medications, such as sulfasalazine, Mesalazine, or Colazol, although they are not as effective as suppositories for proctitis.